# Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms

> **NCT00912535** · PHASE4 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 39 (actual)

## Conditions studied

- Primary Anxiety Disorders
- Mood Disorders With Comorbid Anxiety Symptoms

## Interventions

- **DRUG:** Quetiapine extended release tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00912535
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912535, "Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00912535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*